Shionogi & Co (SGIOY) Fair Value & Analysis
Healthcare · US · Market cap $14.8B
Shionogi & Co
SGIOY · US
Fair value as of: Jul 18, 2026
From 25 valuation models · updated 7 days ago
Price vs Fair Value (12 months)
12‑month range $7.75 – $11.48 · fair‑value band $10.62 – $20.25 · the $8.70 price screens below the $13.91 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shionogi & Co (SGIOY) currently trades at $8.70, while our model-based Fair Value estimate is $13.91, implying the stock looks roughly 59.9% undervalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Shionogi & Co generated revenue of $500B at a net margin of 41.1%. Revenue grew 32.8% year over year. It earns a return on equity of 13.5%. The balance sheet holds a net cash position of $27.1B. Fundamentals as of Jul 18, 2026
Our scenario range runs from $10.62 (bear case) to $20.25 (bull case); at $8.70, the current price sits below that range. The share trades about 24% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 60%, SGIOY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Shionogi & Co reported revenue of $530B in FY2026 versus $335B in FY2022, a compound +12.1%/yr. Reported net income was $218B in FY2026, compounding +17.5%/yr from FY2022.
Is SGIOY fairly valued? → Check now
Recent news
- ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting inj
- Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
- FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-nega
- Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating Y
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,247 | ₹2,697 | +20% |
| Mankind Pharma Limited MANKIND | ₹2,336 | ₹1,068 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shionogi & Co (SGIOY) undervalued?
What is the fair value of SGIOY?
What is the quality score of SGIOY?
What is the revenue of Shionogi & Co (SGIOY)?
What is the net profit margin of SGIOY?
Does Shionogi & Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Shionogi & Co analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.